October 03, 2023
The Therapeutics Accelerator (the ‘Accelerator’) will identify, fund and advance innovative projects from academic partners in the U.K. and U.S. with the goal to deliver 40 new potentially life-changing therapies for rare diseases into clinical trials over the next ten years, targeting multiple approvals in key...
Continue ReadingJune 06, 2016
When the Lauder family founded the Alzheimer’s Drug Discovery Foundation (ADDF) in 1998, they knew that proprietary boundaries would only limit efforts to develop effective Alzheimer’s drugs. So they resolved to make the ADDF’s knowledge available to everyone working to overcome this devastating disease—and all the... Continue Reading
May 02, 2016
CLEVELAND AND INDIANAPOLIS – May 2, 2016 – BioMotiv, a drug development accelerator associated with the Harrington Project, and Indiana University Research and Technology Corp. announce the formation of a new biotechnology start-up, Allinaire Therapeutics. Allinaire Therapeutics aims to develop novel therapeutics for... Continue Reading
April 18, 2016
LONDON, APRIL 18, 2016: - Arix Bioscience Limited (Arix Bioscience), formerly Perceptive Bioscience Investments Limited, a global healthcare and life science company supporting medical innovation, announced today it has agreed to provide up to $25 million capital to BioMotiv LLC, a US-based therapeutic accelerator organization... Continue Reading
April 13, 2016
WILMINGTON, MA, April 13, 2016 – Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a strategic partnership with BioMotiv, LLC, the therapeutic accelerator company associated with The Harrington Project for Discovery & Development. Through this partnership, Charles River will... Continue Reading
March 15, 2016
CLEVELAND – The third annual Harrington Prize for Innovation in Medicine has been awarded to Jeffrey M. Friedman, MD, PhD, of The Rockefeller University, New York City, for his discovery of leptin and the leptin-mediated pathway that controls feeding behavior.The Harrington Prize for Innovation in Medicine, established in... Continue Reading
February 29, 2016
Formed by BioMotiv and Rutgers UniversityCLEVELAND AND NEW BRUNSWICK— FEBRUARY 29, 2016— BioMotiv, a drug development accelerator associated with The Harrington Project, and Rutgers, the State University of New Jersey, are announcing the formation of a new biotechnology startup, Z53 Therapeutics. Z53 Therapeutics aims to... Continue Reading
January 13, 2016
Cleveland, Ohio – The Harrington Discovery Institute at University Hospitals (UH) in Cleveland, Ohio has announced the 2016 recipients of Harrington Scholar-Innovator Awards. The awards support breakthrough work of physician-scientists whose discovery research shows promise of advancing the standard of care.The Harrington... Continue Reading
January 08, 2016
Cleveland– January 8, 2016 – Dual Therapeutics, LLC (“Dual Therapeutics”) today announced a strategic collaboration with Bristol-Myers Squibb (NYSE: BMY) to advance small molecule compounds for the treatment of cancer and other diseases. Dual Therapeutics’ small-molecule modulators simultaneously block multiple cancer... Continue Reading